RU-486 Suspension and Review Act of 2007
Latest action · Feb 2, 2007 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 4, 2007
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
RU-486 Suspension and Review Act of 2007 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.
Deems the drug misoprostol to be misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.
Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.
Cosponsors 48
Members who signed on, in the order they did. Signatures ran from Jan 17, 2007 to May 20, 2008.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-ID | Bill Sali | Jan 17, 2007 | |
| R-GA | Charles W. Norwood | Jan 17, 2007 | |
| R-NJ | Christopher H. Smith | Jan 17, 2007 | |
| R-IL | Donald A. Manzullo | Jan 17, 2007 | |
| R-KY | Geoff Davis | Jan 17, 2007 | |
| R-NE | Jeff Fortenberry | Jan 17, 2007 | |
| R-VA | Jo Ann Davis | Jan 17, 2007 | |
| R-SC | Joe Wilson | Jan 17, 2007 | |
| D-TN | Lincoln Davis | Jan 17, 2007 | |
| R-CO | Marilyn N. Musgrave | Jan 17, 2007 | |
| R-TN | Marsha Blackburn | Jan 17, 2007 | |
| R-MI | Peter Hoekstra | Jan 17, 2007 | |
| R-GA | Phil Gingrey | Jan 17, 2007 | |
| R-LA | Rodney Alexander | Jan 17, 2007 | |
| R-MS | Roger F. Wicker | Jan 17, 2007 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 4, 2007 |
| Health Subcommittee | Referred Feb 2, 2007 |
Actions 3
Everything that happened, newest first.
- Feb 2, 2007Referred to the Subcommittee on Health.
- Jan 4, 2007Introduced in House
- Jan 4, 2007Referred to the House Committee on Energy and Commerce.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug commonly known as RU-486 is deemed to have been withdrawn, to provide for the review by the Comptroller General of the United States of the process by which the Food and Drug Administration approved such drug, and for other purposes.
- Short Titles as Introduced
- RU-486 Suspension and Review Act of 2007
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Abortion
- Administrative procedure
- Commerce
- Congress
- Congressional investigations
- Congressional reporting requirements
- Congressional veto
- Department of Health and Human Services
- Drug approvals
- Drugs
- Food and Drug Administration (FDA)
- Government Operations and Politics
- Government publicity
- Health
- Labeling
- Law
Text 1
Each version as it was printed, newest first.
- Jan 4, 2007Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.